These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 25928516

  • 1. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL, Neto LV, Lima GA, Gabrich R, Miranda LC, Gadelha MR.
    Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
    [Abstract] [Full Text] [Related]

  • 2. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 3. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J, Diamandi A, Mistry J, Scorilas A.
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [Abstract] [Full Text] [Related]

  • 4. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F.
    Urol Int; 2008 Feb; 80(1):68-73. PubMed ID: 18204237
    [Abstract] [Full Text] [Related]

  • 5. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 6. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 7. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia.
    Sreenivasulu K, Nandeesha H, Dorairajan LN, Rajappa M, Vinayagam V.
    Clin Chim Acta; 2017 Jun 01; 469():37-41. PubMed ID: 28300542
    [Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb 01; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 9. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK, Han BK, Jeong JS, Jeong SJ, Moon KH, Byun SS, Lee SE.
    Asian J Androl; 2008 Mar 01; 10(2):207-13. PubMed ID: 18097534
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar 01; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 11. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 01; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 12. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
    Safarinejad MR, Shafiei N, Safarinejad S.
    Growth Horm IGF Res; 2011 Jun 01; 21(3):146-54. PubMed ID: 21536469
    [Abstract] [Full Text] [Related]

  • 13. Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading.
    Terracciano D, Bruzzese D, Ferro M, Mazzarella C, Di Lorenzo G, Altieri V, Mariano A, Macchia V, Di Carlo A.
    Prostate; 2012 Jan 01; 72(1):100-7. PubMed ID: 21520165
    [Abstract] [Full Text] [Related]

  • 14. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer.
    Daragó A, Sapota A, Matych J, Nasiadek M, Skrzypińska-Gawrysiak M, Kilanowicz A.
    Clin Chem Lab Med; 2011 Oct 01; 49(10):1699-705. PubMed ID: 21671822
    [Abstract] [Full Text] [Related]

  • 15. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z, Jieming L, Su L, Wenlu S.
    J Surg Oncol; 2007 Jul 01; 96(1):54-61. PubMed ID: 17345593
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
    Finne P, Auvinen A, Koistinen H, Zhang WM, Määttänen L, Rannikko S, Tammela T, Seppälä M, Hakama M, Stenman UH.
    J Clin Endocrinol Metab; 2000 Aug 01; 85(8):2744-7. PubMed ID: 10946875
    [Abstract] [Full Text] [Related]

  • 17. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E.
    Cancer Causes Control; 2005 Apr 01; 16(3):255-62. PubMed ID: 15947877
    [Abstract] [Full Text] [Related]

  • 18. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO, Akanji AO, Mojiminiyi OA, Bashir AA, Daar AS, Varghese R.
    Prostate Cancer Prostatic Dis; 2005 Apr 01; 8(1):84-90. PubMed ID: 15775992
    [Abstract] [Full Text] [Related]

  • 19. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schröder FH.
    J Clin Endocrinol Metab; 2004 Sep 01; 89(9):4391-6. PubMed ID: 15356036
    [Abstract] [Full Text] [Related]

  • 20. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease.
    Grosman H, Fabre B, Lopez M, Scorticati C, Lopez Silva M, Mesch V, Mazza O, Berg G.
    Aging Male; 2016 Sep 01; 19(1):40-5. PubMed ID: 26526283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.